ARA-290

ARA-290 is a synthetic peptide derived from erythropoietin (EPO), designed to retain EPO’s tissue-protective effects while avoiding its hematopoietic activity. It has been investigated for its role in neuropathic pain, inflammation, and tissue repair.

Developed to harness the cytoprotective properties of EPO, ARA-290 targets the innate repair receptor (IRR) rather than erythropoietin receptors, making it a promising candidate for chronic inflammation and neurodegeneration..

Research into ARA-290 has been largely focused on its ability to activate the innate repair receptor (IRR), which plays a key role in reducing inflammation, protecting tissues, and promoting healing. This receptor activation differentiates ARA-290 from traditional EPO therapies and has led to studies exploring its impact on nerve function, metabolic health, and auto-immune conditions.

Neuroprotection & Neuropathic Pain Relief

• ARA-290 has been studied for its role in reducing nerve damage and alleviating neuropathic pain, particularly in conditions like diabetes-induced neuropathy.
• It interacts with the innate repair receptor (IRR), which supports neuronal survival and function.

Anti-Inflammatory & Autoimmune Modulation

• Research suggests ARA-290 may suppress inflammatory cytokines and promote immune balance, making it a promising candidate for autoimmune disorders.
• It has been studied in inflammatory conditions such as sarcoidosis and systemic inflammatory diseases.

Tissue Protection & Wound Healing

• The peptide has been investigated for its role in repairing damaged tissues, particularly in the vascular system, muscles, and nervous system.
• It may aid in accelerating recovery following injuries or degenerative conditions.

Metabolic & Cardiovascular Health

• Studies have explored its impact on glucose metabolism and insulin sensitivity, suggesting potential applications in managing metabolic disorders like diabetes.
• Some findings indicate ARA-290 may improve vascular function and endothelial health, contributing to cardiovascular wellness.

ARA-290 and Small Fiber Neuropathy (SFN) in Sarcoidosis

• Study Overview: A clinical study published in the Journal of Translational Medicine evaluated the effects of ARA-290 on small fiber neuropathy in patients with sarcoidosis.
• Findings: The study reported significant improvements in neuropathic pain and autonomic function, with reduced inflammation and enhanced nerve regeneration.
• Conclusion: ARA-290 demonstrated a potential therapeutic effect in alleviating neuropathy-related symptoms without affecting red blood cell levels.

ARA-290’s Role in Reducing Chronic Inflammation

• Study Overview: Preclinical studies investigated ARA-290's ability to reduce systemic inflammation in autoimmune conditions.
• Findings: Researchers observed a decrease in pro-inflammatory markers, particularly in conditions involving chronic immune activation.
• Conclusion: The peptide may serve as an alternative anti-inflammatory agent with fewer side effects than traditional immunosuppressive drugs.

Neuroprotective Effects in Diabetes-Related Neuropathy

• Study Overview: Researchers assessed ARA-290’s effect on diabetic patients experiencing neuropathic pain.
• Findings: Subjects who received ARA-290 reported decreased pain and improved sensory nerve function compared to a placebo group.
• Conclusion: The study suggested that ARA-290 could be a promising candidate for treating diabetes-induced nerve damage.